SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is trending due to its rapidly expanding ecosystem, evidenced by rising TVL, app revenue, and user growth, driven by its advanced ZK-STARK technology, increasing Bitcoin DeFi integrations, and ongoing focus on quantum resistance and privacy. The community widely discusses its robust long-term infrastructure build, viewing current valuations as a potential mispricing despite recent token unlock conversations.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following news of a public stock offering and a substantial royalty funding agreement, which the community is debating as either a necessary strategic capital raise to advance its oncology pipeline and meet financial obligations, or as a significant, ill-timed dilution impacting short-term share value.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL (GRAL) is highly debated after trial results for its multi-cancer early detection test missed a primary endpoint for statistically significant reduction in late-stage diagnoses. This has fueled a polarized discussion between those seeing an overreaction given the test's strong detection capabilities and ample cash runway, and others expressing significant concern for the company's future.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending after its Q4 earnings, which showed strong revenue growth but an EPS miss, as the company prioritizes significant investments in pipeline expansion, including a new patent extending protection to 2042 and dosing the first patient in a Phase 3 CIC trial. Investors are debating the short-term impact of increased expenses versus the long-term value from a potential buyout and rising analyst price targets, despite general market volatility.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - 8% PRF PERPETUAL USD 100 - Ser A

Strategy Inc 8.00% Series A Perpetual Strike Preferred Stock

Strategy Inc's 8.00% Series A Perpetual Strike Preferred Stock ($STRK) is a focal point of conversation, with investors debating its attractive dividend yield and direct correlation to MicroStrategy's Bitcoin acquisition strategy. However, the community also expresses notable concerns over potential dividend sustainability, dilution risks from new preferred offerings, and its value relative to other MicroStrategy preferred shares.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is heavily discussed as it experiences significant price fluctuations, with the community divided on short-term outlooks while the ecosystem sees increasing institutional interest in staking loans and new privacy solutions like GhostwareOS, bolstering its push to scale traditional finance on-chain.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending sharply lower following a reported Q4 loss and cautious Q1 forecast, largely impacted by increased credit loss provisions. The community is actively debating the long-term viability of its Buy Now, Pay Later model and its path to profitability, with some viewing the significant price drop as an overreaction.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token ($VVV) is trending amid significant token supply reductions, including burns and reduced emissions, alongside surging platform activity and strategic partnerships in the privacy-focused AI sector. The community is highly optimistic, discussing its unique uncensored AI offerings and low circulating supply as key drivers for substantial future growth.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending with high anticipation for its upcoming Investor Day, where new data on its best-in-class sonelokimab nanobody is expected, driving community excitement amidst significant institutional share repurchases and speculation about a potential short squeeze from its current undervaluation.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is experiencing a sharp surge driven by robust earnings and bullish guidance tied to its essential optical solutions for AI data centers, yet the community is fiercely divided between celebrating its "unstoppable" momentum and warning of extreme overvaluation and insider selling.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Brokerages

AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) has received a consensus recommendation of "Hold" from the six ratings firms that are presently covering the stock, Marketbeat reports. One...

AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL) will be releasing its Q4 2025 earnings after the market closes on Tuesday, February 24. (View Earnings Report at...

AbCellera Biologics (NASDAQ:ABCL) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen raised shares of AbCellera Biologics from a "sell" rating to a "hold" rating in a report on Saturday...

AbCellera Biologics (NASDAQ:ABCL) Trading Up 8.3% - Still a Buy?

AbCellera Biologics (NASDAQ:ABCL) Trading 8.3% Higher - Here's What Happened...

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference, March 4, 2026 KeyBanc Capital Markets...

AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.1% - Here's Why

AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.1% - Here's What Happened...

AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6% - Here's Why

AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6% - What's Next...

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera (Nasdaq: ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the...

AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded shares of AbCellera Biologics from a "hold" rating to a "sell" rating in a research report on Tuesday...

Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL

Citizens Financial Group Inc. RI bought a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the third quarter, according to the company in its most recent 13F filing with...

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

ABCL
AbCellera Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABCL News

ABCLAbCellera Biologics Inc